Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of May 2026, specifically reporting on share repurchase transactions executed between May 18 and May 22, 2026. The company is a global biopharma firm headquartered in London, United Kingdom.
Key Financial Metrics and Transaction Details
The filing details a non-discretionary share buyback program executed through Citigroup Global Markets Limited. The following table summarizes the daily purchase activity:
| Date | Shares Purchased | Lowest Price (GBp) | Highest Price (GBp) | VWAP (GBp) |
|---|---|---|---|---|
| 18 May 2026 | 339,102 | 1,847.00 | 1,882.00 | 1,867.02 |
| 19 May 2026 | 336,572 | 1,872.50 | 1,909.00 | 1,890.81 |
| 20 May 2026 | 332,060 | 1,886.00 | 1,914.00 | 1,899.43 |
| 21 May 2026 | 332,672 | 1,883.00 | 1,918.50 | 1,902.38 |
| 22 May 2026 | 329,892 | 1,906.00 | 1,927.00 | 1,918.46 |
Cumulative Activity: Since May 11, 2026, the company has purchased 3,342,149 ordinary shares. The purchased shares are held as Treasury shares.
Capital Structure Post-Transaction:
- Treasury Shares: 264,720,435
- Shares in Issue (excluding Treasury): 4,051,501,116
- Total Voting Rights: 4,051,501,116
- Treasury Share Voting Percentage: 6.53%
Note: This filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the reduction in outstanding shares due to the buyback program and the corresponding increase in Treasury shares. The filing does not report material changes to operating results or financial position compared to prior periods.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. It notes that actual results may differ materially from projections due to risks and uncertainties. Specific risk factors are referenced in GSK's Annual Report on Form 20-F for 2025 and Q1 Results for 2026, but are not detailed in this document. No new guidance or outlook was provided in this specific filing.
Investor Verification Checklist
- Verify the total number of shares in issue (4,051,501,116) for calculating ownership thresholds under FCA Disclosure Guidance and Transparency Rules.
- Confirm the percentage of voting rights held in treasury (6.53%) to assess potential dilution or voting power dynamics.
- Review the full breakdown of individual purchases via the provided RNS link for granular trading data.
- Consult the referenced 2025 Form 20-F and 2026 Q1 Results for comprehensive risk factors and financial performance metrics not included here.